Overview

* Resmed ( RMD ) fiscal Q1 revenue grows 9% to $1.34 bln, narrowly beating analyst expectations

* Adjusted EPS for fiscal Q1 beats consensus, reflecting strong operational performance

* Company repurchased 523,000 shares for $150 mln, continuing capital management strategy

Outlook

* Company did not provide specific guidance for future quarters or full year in its press release

Result Drivers

* SLEEP DEVICES DEMAND - Revenue growth driven by increased demand for sleep devices, masks, and accessories

* MARGIN IMPROVEMENT - Gross margin increased due to manufacturing and logistics efficiencies and component cost improvements

* RESTRUCTURING CHARGES - $16 mln restructuring charges recorded due to workforce planning activities

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q1 Miss $1.34 $1.33

Revenue bln bln (16

Analysts

)

Q1 Beat $2.55 $2.49

Adjusted (13

EPS Analysts

)

Q1 EPS $2.37

Q1 62%

Adjusted

Gross

Margin

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 13 "strong buy" or "buy", 7 "hold" and 1 "sell" or "strong sell"

* The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

* Wall Street's median 12-month price target for Resmed Inc ( RMD ) is $300.00, about 15.5% above its October 29 closing price of $253.62

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)